azilsartan medoxomil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic) 4322 863031-21-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • TAK 491
  • edarbi
  • azilsartan medoxomil
  • azilsartan kamedoxomil
an angiotensin type 1 receptor blocker; receptor blocker
  • Molecular weight: 568.54
  • Formula: C30H24N4O8
  • CLOGP: 4.24
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 1
  • TPSA: 139.57
  • ALOGS: -4.91
  • ROTB: 10

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 2011 FDA ARBOR PHARMS IRELAND

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Renal impairment 49.38 21.52 33 1850 74339 46609840
Hepatic function abnormal 43.08 21.52 23 1860 34398 46649781
Cerebral infarction 42.14 21.52 20 1863 23346 46660833
Platelet count decreased 32.40 21.52 29 1854 99995 46584184
Hyperkalaemia 30.05 21.52 21 1862 50688 46633491
Hypertension 28.18 21.52 37 1846 196319 46487860
Decreased appetite 25.48 21.52 35 1848 193801 46490378
Product odour abnormal 23.30 21.52 6 1877 1130 46683049

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral infarction 90.35 20.94 43 2281 26330 29923824
Hepatic function abnormal 69 20.94 42 2282 41903 29908251
Renal impairment 60.77 20.94 51 2273 84133 29866021
Fibrillary glomerulonephritis 53.23 20.94 8 2316 41 29950113
Interstitial lung disease 46.57 20.94 38 2286 60159 29889995
Proteinuria 31.29 20.94 18 2306 16127 29934027
Nephrotic syndrome 29.06 20.94 13 2311 6872 29943282
Thrombotic cerebral infarction 27.25 20.94 6 2318 299 29949855
Altered state of consciousness 25.36 20.94 17 2307 19902 29930252
Hepatocellular carcinoma 24.94 20.94 13 2311 9597 29940557
Hyperuricaemia 22.09 20.94 11 2313 7383 29942771
Haemorrhagic cerebral infarction 21.60 20.94 6 2318 780 29949374
Decreased appetite 21.21 20.94 40 2284 149870 29800284

Pharmacologic Action:

SourceCodeDescription
ATC C09CA09 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
Angiotensin II receptor blockers (ARBs), plain
ATC C09DA09 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and diuretics
MeSH PA D047228 Angiotensin II Type 1 Receptor Blockers
MeSH PA D057911 Angiotensin Receptor Antagonists
FDA MoA N0000180999 Angiotensin 2 Type 1 Receptor Antagonists
FDA EPC N0000175561 Angiotensin 2 Receptor Blocker
FDA PE N0000178477 Decreased Blood Pressure
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:50266 prodrugs
CHEBI has role CHEBI:61016 angiotensin receptor antagonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Hypovolemia contraindication 28560003
Low blood pressure contraindication 45007003
Hyponatremia contraindication 89627008
Impaired renal function disorder contraindication 197663003
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.11 acidic
pKa2 3.02 Basic
pKa3 2.4 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Type-1 angiotensin II receptor GPCR ANTAGONIST UNKNOWN CHEMBL
Type-1 angiotensin II receptor GPCR IC50 6.38 CHEMBL

External reference:

IDSource
WEC6I2K1FC UNII
D08067 KEGG_DRUG
863031-24-7 SECONDARY_CAS_RN
147403-03-0 SECONDARY_CAS_RN
4030593 VANDF
4030594 VANDF
C2698290 UMLSCUI
C1958569 UMLSCUI
CHEBI:68845 CHEBI
CHEBI:68850 CHEBI
CHEMBL2103795 ChEMBL_ID
CHEMBL2028661 ChEMBL_ID
DB08822 DRUGBANK_ID
CHEMBL57242 ChEMBL_ID
23699544 PUBCHEM_CID
8874 INN_ID
C557413 MESH_SUPPLEMENTAL_RECORD_UI
6900 IUPHAR_LIGAND_ID
C521273 MESH_SUPPLEMENTAL_RECORD_UI
8724 INN_ID
F9NUX55P23 UNII
135415867 PUBCHEM_CID
6901 IUPHAR_LIGAND_ID
1091642 RXNORM
180314 MMSL
27787 MMSL
d07754 MMSL
013661 NDDF
013662 NDDF
448917007 SNOMEDCT_US
449042005 SNOMEDCT_US
449561004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Edarbi HUMAN PRESCRIPTION DRUG LABEL 1 60631-040 TABLET 40 mg ORAL NDA 32 sections
Edarbi HUMAN PRESCRIPTION DRUG LABEL 1 60631-080 TABLET 80 mg ORAL NDA 32 sections
Edarbyclor HUMAN PRESCRIPTION DRUG LABEL 2 60631-412 TABLET 40 mg ORAL NDA 32 sections
Edarbyclor HUMAN PRESCRIPTION DRUG LABEL 2 60631-425 TABLET 40 mg ORAL NDA 32 sections